| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Product revenue, net | 66,018 | 32,657 | ||
| Cost of goods sold | 1,141 | 696 | ||
| Research and development | 8,405 | 9,147 | ||
| Selling, general and administrative | 33,753 | 28,238 | ||
| Change in fair value of contingent consideration | 614 | 1,101 | ||
| Total operating expenses | 43,913 | 39,182 | ||
| Operating income (loss) | 22,105 | -6,525 | ||
| Interest income, net | 5,298 | 3,193 | ||
| Interest expense | 1,390 | 1,376 | ||
| Total other income (expense), net | 3,908 | 1,817 | ||
| Net income (loss) | 26,013 | -4,708 | ||
| Net unrealized gain (loss) on marketable securities | 261 | -153 | ||
| Foreign currency translation adjustment | 14 | 12 | ||
| Total comprehensive income (loss) | 26,288 | -4,849 | ||
| Earnings per share, basic | 0.49 | -0.09 | ||
| Earnings per share, diluted, total | 0.47 | -0.09 | ||
| Weighted average number of shares outstanding, basic | 53,328,094 | 50,483,281 | ||
| Weighted average number of shares outstanding, diluted | 54,921,916 | 50,483,281 | ||
SOLENO THERAPEUTICS INC (SLNO)
SOLENO THERAPEUTICS INC (SLNO)